Genzyme Develops Beijing R&D Center
Genzyme Corp. is planning to construct a new 200,000-sf R&D center in the Zhongguancun Life Science Park in Beijing. The $90 million facility will accommodate research and development in areas including orthopedics, transplant and immune disease, oncology, endocrinology, and cardiovascular disease, as well as laboratory-scale operations for the MACI(R) (matrix-induced autologous chondrocyte implantation) cell therapy and polyclonal antibody operations.